Epicrispr wins $8M from California's stem cell agency for its FSHD epigenetic therapy

Epicrispr Biotechnologies has been awarded $8 million by the California Institute for Regenerative Medicine (CIRM) to support its first-in-human trial of EPI-321 in facioscapulohumeral muscular dystrophy (FSHD). The San Francisco company announced the grant on 19 October. It comes through CIRM's Clinical Trial Stage Projects programme.

What EPI-321 does

FSHD is a progressive genetic muscle disease driven by a gene called DUX4 being active when it should be silent. Epicrispr estimates it affects more than 1 million people worldwide, and there is no approved treatment that changes the course of the disease.

EPI-321 is given once, by IV infusion. A single AAV vector carries it to muscle, where it is designed to shut DUX4 down through epigenetic changes rather than by altering the DNA sequence itself. The company describes EPI-321 as first in its class. Epicrispr's proprietary technology platform is called the Gene Expression Modulation System (GEMS).

Where the trial is

The open-label Phase 1/2 study is enrolling adults with FSHD and looking at safety, tolerability and early signs of biological and clinical activity. Epicrispr says interim results have shown statistically significant gains in whole-body lean muscle volume on MRI, along with favourable biomarker, strength and function readings and a manageable safety profile.

Six-month data were presented at the 31st Annual Congress of the World Muscle Society. CRISPR Medicine News summarised them: across the first six patients, upper-body lean muscle volume rose 3.0%, against a predicted 3.5% decline in comparators, and upper-body strength rose 4.1%. No treatment-related serious adverse events were reported. It is a small, early dataset, but it gives the programme something concrete to build on.

"FSHD is a devastating progressive neuromuscular disease with no approved disease-modifying treatments." Maria Chiuchiolo, PhD, science officer in clinical development, CIRM

Who's behind it

Epicrispr is led by CEO Amber Salzman, Ph.D., who called the award important validation of the company's epigenetic editing approach. CIRM's award record lists the grant as CLIN2-20392, with Weston Miller as principal investigator. CIRM itself has received $8.5 billion from Californians since 2004.

The bigger picture

Grant money matters more than usual in cell and gene therapy right now. BioPharma Dive reported in July that the sector remains in a multi-year slump, on pace for about $2 billion of venture funding in 2026. Non-dilutive awards like this one let small companies push trials forward without going back to investors on weaker terms.